Established in 1973, the GSK Irvine site is a world leader in the primary manufacture of antibiotics. 330 people work at Irvine with plant operations running on a continuous 24 hour schedule every day of the year.
The strategic role of the Irvine site is to be a secure, competitive supplier of 6-APA and Potassium Clavulanate to support GSK's anti-infectives franchises and the needs of external customers and patients.
To support the increased market demand for Augmenten, of which Potassium Clavulanate is a key primary ingredient, G&T is working with GSK to increase the manufacturing capacity of the plant from 900t/year to 1250t/year. This will mean substantial increases to the existing building cubic capacity and appropriate additional process equipment and utilities.